Bioengineered skin and soft tissue substitutes are generally derived from autologous or allogeneic human tissue, xenographic tissue, synthetic materials, or a composite. These products are being used and evaluated for treating a variety of conditions, such as breast reconstruction, thermal injury treatment, plastic surgeries, lower extremity ulcers, and others. Bioengineered and soft tissue substitutes can either be acellular or cellular. Acellular dermal matrix (ADM) contains a scaffold or matrix of materials like hyaluronic acid, collagen, and fibronectin. ADM products can be based on species sources, additives, hydration, tissue source, and preparation mode. Cellular products incorporate living cells, such as keratinocytes and fibroblasts, embedded in a matrix. The such cellular matter could be allogeneic, autologous, or even derived from another species. Skin substitutes are usually composed of epidermal cells, dermal cells, or a combination of both and provide growth factors.
Non-healing wounds are a chief application area of bioengineered skin and skin substitute products. This area potentially included diabetic ulcers, pressure ulcers, and vascular insufficiency ulcers. Such wounds do not adequately heal with conventional wound care and may lead to prolonged morbidity and an augmented risk of mortality. Bioengineered skin substitutes have the potential to improve healing rates in such treatments in a shorter amount of time and reduce the risk of complications. Second- and third-degree burns can also be effectively treated with bioactive skin and skin substitutes.
The global market for bioengineered skin and skin substitutes is segmented on the following bases:
Product Type
Acellular dermal matrix
Amniotic membrane
Collagen scaffold
Living cell therapy
Biosynthetic products
Geography
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Russia
Rest of Europe
Asia-Pacific
India
China
Japan
Rest of Asia-Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC Countries
South Africa
Rest of Middle East and Africa
Key players identified for the bioengineered skin and skin substitutes market include, but are not limited to:
An overview of the global markets for bioengineered skin and skin substitutes
Market trends assessment for the period 2013-2023, with historical information for 2013 and 2014 and projections through 2023, with respective CAGRs during 2016 and 2023
Qualitative assessment tools such as market drivers, challenges, future prospects, major commercial events, etc.
Market competition scrutiny tools such as market share analysis, an attractive investment proposition, and Porter’s Five Forces model
Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
A general overview of the industry structure
Company profiles highlight key information about the major players operating in the bioengineered skin and skin substitutes market.
Frequently Asked Questions:
The market for Bioengineered Skin And Skin Substitutes Market is expected to reach USD XX Bn By 2023.
The Bioengineered Skin And Skin Substitutes Market is expected to see significant CAGR growth over the coming years, at XX%.
The report is forecasted from 2023.
The base year of this report is 2022.
LifeCell Corp., Bard Davol, Ethicon, LifeNet Health, Synthes, Tissue Regenix Wound Care, KCI, TEI Biosciences, Covidien plc, MiMedix, BioD, NuTech Medical, AlloSource, Medline Industries, Cook Biotech, Organogenesis, Shire Regenerative Medicine,are some of the major players in the global market.
